Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Partial agonists for A(3) adenosine receptors.

Zhan-Guo Gao1, Kenneth A Jacobson

  • 1Molecular Recognition Section, Laboratory of Bioengineering, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892-0810, USA. zhanguog@intra.niddk.nih.gov

Current Topics in Medicinal Chemistry
|April 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A<sub>2B</sub> adenosine receptor antagonists.

Biochemical pharmacology·2022
Same author

Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor.

Molecules (Basel, Switzerland)·2022
Same author

International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Pharmacological reviews·2022
Same author

Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.

Current opinion in pharmacology·2022
Same author

Interaction of A<sub>3</sub> adenosine receptor ligands with the human multidrug transporter ABCG2.

European journal of medicinal chemistry·2022
Same author

Bridged Piperidine Analogues of a High Affinity Naphthalene-Based P2Y<sub>14</sub>R Antagonist.

Journal of medicinal chemistry·2022
Same journal

Overview of Immunotherapy in Lung Cancer: Present Landscape.

Current topics in medicinal chemistry·2026
Same journal

Exploration of a Novel Physicochemical Property Space for the Development of Antimalarial Drugs.

Current topics in medicinal chemistry·2026
Same journal

Computational Drug Design of Natural Product-Based Azole Hybrids for Multifactorial Diseases: Success Stories.

Current topics in medicinal chemistry·2026
Same journal

Simulated Natural Nanoparticles in Bai-Hu-Tang Decoction: Preparation, Characterization, Pharmacokinetics, and Antipyretic Effects.

Current topics in medicinal chemistry·2026
Same journal

Dolabellane Diterpenes from the Marine Brown Alga Dictyota dolabellana and their Potential Antiviral Activity.

Current topics in medicinal chemistry·2026
Same journal

Inhibitory Effects of Flavonoids from the Stems and Leaves of Scutellaria baicalensis Georgi on Oligodendrocyte Pyroptosis Induced by Aβ1-42.

Current topics in medicinal chemistry·2026
See all related articles

Selective agonists for A(3) adenosine receptors (ARs) show therapeutic potential for ischemic conditions. Structural modifications significantly impact A(3)AR efficacy, guiding the development of potent partial agonists.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Selective agonists for A(3) adenosine receptors (ARs) are potential therapeutics for ischemic conditions.
  • Partial agonists may offer improved selectivity over full agonists.
  • Understanding structural determinants of A(3)AR activation is crucial for drug design.

Purpose of the Study:

  • To identify structural modifications influencing A(3)AR activation and efficacy.
  • To explore the potential of adenosine derivatives as selective A(3)AR agonists or antagonists.
  • To guide the development of potent and selective partial agonists for A(3)AR.

Main Methods:

  • Systematic modification of adenosine derivatives, focusing on substituents at various positions (N(6), ribose, chloro, fluoro, thio).

Related Experiment Videos

  • Evaluation of compound efficacy and selectivity at A(3)AR and other adenosine receptor subtypes.
  • Structure-activity relationship (SAR) analysis to correlate chemical structure with biological activity.

    • Main Results:

    • Specific substitutions like 2-chloro and N(6)-benzyl significantly modulated A(3)AR activity, leading to antagonism or partial agonism.
    • 2'- and 3'- substitutions on the ribose moiety had a pronounced effect on efficacy.
    • N(6)-benzyl substitution reduced efficacy but enhanced selectivity for human A(3)AR compared to N(6)-methyl.
    • The A(2A)AR agonist DPMA acted as an antagonist at the human A(3)AR.

    Conclusions:

    • Adenosine derivative efficacy at A(3)AR is highly sensitive to subtle structural changes.
    • Rational design and screening of adenosine derivatives can identify potent and selective A(3)AR partial agonists.
    • These findings provide a foundation for developing novel therapeutics targeting A(3)AR for various diseases.